Vanguard Capital Management
FBRX icon

Vanguard Capital Management’s Forte Biosciences FBRX Stock Holding History

Vanguard Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
861,737
+330,045
+62% +$7.83M ﹤0.01% 2493
2026
Q1 		$13.8M Buy
+531,692
New +$15.3M ﹤0.01% 2555

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management's FBRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Forte Biosciences (FBRX) stake by 62% in Q2 2026, buying an estimated $7.83M and bringing the position to 861,737 shares worth $18.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2493.

Vanguard Capital Management first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. 85 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Vanguard Capital Management held 861,737 shares of Forte Biosciences worth $18.3M as of Q2 2026.
  • Vanguard Capital Management bought 330,045 Forte Biosciences shares in Q2 2026, an estimated $7.83M.
  • Forte Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2493 holding.
  • Vanguard Capital Management first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 85 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.